GADOLIN trial: In follicular lymphoma patients who were refractory to a rituximab-containing regimen

Overall survival: a post hoc analysis of GAZYVA + bendamustine followed by GAZYVA monotherapy vs bendamustine alone

At the median observation time of 24.1 months, median overall survival was not yet reached (HR=0.62; 95% CI, 0.39-0.98) 1

GAZYVA GADOLIN Secondary Endpoint: Overall Survival Chart